Lessons for fragment library design: analysis of output from multiple screening campaigns

Over the past 8 years, we have developed, refined and applied a fragment based discovery approach to a range of protein targets. Here we report computational analyses of various aspects of our fragment library and the results obtained for fragment screening. We reinforce the finding of others that the experimentally observed hit rate for screening fragments can be related to a computationally defined druggability index for the target. In general, the physicochemical properties of the fragment hits display the same profile as the library, as is expected for a truly diverse library which probes the relevant chemical space. An analysis of the fragment hits against various protein classes has shown that the physicochemical properties of the fragments are complementary to the properties of the target binding site. The effectiveness of some fragments appears to be achieved by an appropriate mix of pharmacophore features and enhanced aromaticity, with hydrophobic interactions playing an important role. The analysis emphasizes that it is possible to identify small fragments that are specific for different binding sites. To conclude, we discuss how the results could inform further development and improvement of our fragment library.

[1]  M. Bowman,et al.  Structural basis for high-affinity peptide inhibition of human Pin1. , 2007, ACS chemical biology.

[2]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[3]  Ray A. Jarvis,et al.  Clustering Using a Similarity Measure Based on Shared Near Neighbors , 1973, IEEE Transactions on Computers.

[4]  Heather A Carlson,et al.  Exploring protein-ligand recognition with Binding MOAD. , 2006, Journal of molecular graphics & modelling.

[5]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[6]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[7]  Luhua Lai,et al.  A New Atom-Additive Method for Calculating Partition Coefficients , 1997, J. Chem. Inf. Comput. Sci..

[8]  Pieter F. W. Stouten,et al.  Fast prediction and visualization of protein binding pockets with PASS , 2000, J. Comput. Aided Mol. Des..

[9]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[10]  Renxiao Wang,et al.  The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.

[11]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[12]  John Davies,et al.  Design of small molecule libraries for NMR screening and other applications in drug discovery. , 2002, Current topics in medicinal chemistry.

[13]  L. Mayr,et al.  Structural Analysis of the Mitotic Regulator hPin1 in Solution , 2003, Journal of Biological Chemistry.

[14]  Sergey E Ilyin,et al.  High-Throughput siRNA-Based Functional Target Validation , 2004, Journal of biomolecular screening.

[15]  Roderick E Hubbard,et al.  Informatics and modeling challenges in fragment-based drug discovery. , 2007, Current opinion in drug discovery & development.

[16]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[17]  F. Theil,et al.  New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. , 2004, Journal of medicinal chemistry.

[18]  Peter Ertl,et al.  Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. , 2006, Journal of medicinal chemistry.

[19]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[20]  Sandor Vajda,et al.  Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. , 2007, Journal of medicinal chemistry.

[21]  M. Sundström,et al.  Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water* , 2000, Journal of biomolecular NMR.

[22]  Pascal Furet,et al.  Structure-based design and protein X-ray analysis of a protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.

[23]  E. Kellenberger,et al.  A simple and fuzzy method to align and compare druggable ligand‐binding sites , 2008, Proteins.

[24]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[25]  Gordon M. Crippen,et al.  Prediction of Physicochemical Parameters by Atomic Contributions , 1999, J. Chem. Inf. Comput. Sci..

[26]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[27]  Michael G. Lerner,et al.  Binding MOAD (Mother Of All Databases) , 2005, Proteins.

[28]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[29]  L. Hardy,et al.  The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. , 2004, Drug discovery today.

[30]  Gerhard Klebe,et al.  AffinDB: a freely accessible database of affinities for protein–ligand complexes from the PDB , 2005, Nucleic Acids Res..

[31]  Masaki Tomimoto,et al.  Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[32]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[33]  Peter Ertl,et al.  Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups , 2003, J. Chem. Inf. Comput. Sci..

[34]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[35]  D. Boschelli,et al.  Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors. , 2007, Journal of medicinal chemistry.

[36]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[37]  R. Laskowski.  SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. , 1995, Journal of molecular graphics.

[38]  S. J. Campbell,et al.  Ligand binding: functional site location, similarity and docking. , 2003, Current opinion in structural biology.

[39]  M. Seierstad,et al.  Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. , 2008, Journal of medicinal chemistry.

[40]  Jean M. Severin,et al.  Design of adenosine kinase inhibitors from the NMR-based screening of fragments. , 2000, Journal of medicinal chemistry.

[41]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[42]  Heather A Carlson,et al.  Differences between high- and low-affinity complexes of enzymes and nonenzymes. , 2008, Journal of medicinal chemistry.

[43]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[44]  Didier Rognan,et al.  sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank , 2006, J. Chem. Inf. Model..

[45]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[46]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[47]  Xi Chen,et al.  The Binding Database: data management and interface design , 2002, Bioinform..

[48]  I. Muegge,et al.  Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.

[49]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[50]  Tom Halgren,et al.  New Method for Fast and Accurate Binding‐site Identification and Analysis , 2007, Chemical biology & drug design.

[51]  Alan C. Cheng,et al.  Structure-Based Identification of Small Molecule Binding Sites Using a Free Energy Model , 2006, J. Chem. Inf. Model..

[52]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[53]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[54]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[55]  C L Brooks,et al.  Ligand-protein database: linking protein-ligand complex structures to binding data. , 2001, Journal of medicinal chemistry.

[56]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[57]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[58]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[59]  L. Puskás,et al.  CHEMICAL GENOMICS FOR FASTAND INTEGRATED TARGET IDENTIFICATION AND LEAD OPTIMIZATION , 2004, Medicinal Chemistry Research.

[60]  Ajay N. Jain,et al.  Automatic identification and representation of protein binding sites for molecular docking , 1997, Protein science : a publication of the Protein Society.

[61]  M Hendlich,et al.  LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.

[62]  M. Drysdale,et al.  Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. , 2007, Bioorganic & medicinal chemistry letters.

[63]  D. Goodsell,et al.  Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.

[64]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[65]  B. Honig,et al.  On the nature of cavities on protein surfaces: Application to the identification of drug‐binding sites , 2006, Proteins.

[66]  R. Ranganathan,et al.  Structural and Functional Analysis of the Mitotic Rotamase Pin1 Suggests Substrate Recognition Is Phosphorylation Dependent , 1997, Cell.

[67]  G. Klebe,et al.  Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. , 2002, Farmaco.

[68]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[69]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[70]  L Xue,et al.  Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases. , 1999, Journal of molecular graphics & modelling.

[71]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[72]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[73]  Eric F. Johnson,et al.  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. , 2006, Journal of medicinal chemistry.

[74]  S Subramaniam,et al.  Analytical shape computation of macromolecules: I. molecular area and volume through alpha shape , 1998, Proteins.

[75]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[76]  Ian A. Watson,et al.  Selection of heterocycles for drug design. , 2004, Journal of molecular graphics & modelling.

[77]  Nikolay P Savchuk,et al.  Exploring the chemogenomic knowledge space with annotated chemical libraries. , 2004, Current opinion in chemical biology.

[78]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[79]  Roderick E Hubbard,et al.  The SeeDs approach: integrating fragments into drug discovery. , 2007, Current topics in medicinal chemistry.